A new treatment reduces the risk of a rare type of leukemia by 74%

A treatment, which genetically change the cells of the immune body, has shown the ability to reduce the risk of a rare type of leukemia by 74%, according to the results of a recent study. CiltacabBtagen Autoleucel, known for his commercial name “Carvicti”, underwent a test in a clinical trial that included 419 patients with multiple metal tumor and their cases of chemical “linalidide” usually prescribed to patients. Although the use of this treatment is ‘common’, cases of a large percentage of patients no longer respond to this medicine, according to an oncology specialist, October, during the annual conference of cancer specialists, presented by the American Association of Clinical Oncology in Chicago and during which the results of experiments were presented. Odysis, which did not participate in the study, added that “Carvikti” showed significantly effective results compared to the current patient’s options, “and therefore it can be used safely at an early stage of treatment.” After the patients followed more than 16 months, they found that Celtaccaptins reduced the risk of the disease with 74%. Cleveland Clinic. These are called receptors and able to search and destroy cancer cells. During the clinical experience, the number of unspoken developments, which was dangerous, was slightly higher among the group with ‘(97% compared to 94%), while three -quarters had an excessive immune reaction and about 5% of them of neurological toxicity.